{"success":true,"data":{"pressRelease":{"id":"143751","rtpr_id":"nBw5MxmJRa-20260915","ticker":"GSK","exchange":"LSE","all_tickers":["GSK"],"title":"Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to Advance HIV Response in the U.S.","author":"Business Wire","published_at":"2026-09-15T12:00:02.783Z","article_body":"Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to\nAdvance HIV Response in the U.S.\n\n\n * Ahead of the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare\nannounced it has funded 230 community-based organizations this year to\nstrengthen essential HIV services and help connect people to HIV prevention\nand care\n\nViiV Healthcare, the global specialist HIV company majority owned by GSK, with\nShionogi as a shareholder, today announced more than $33 million in U.S.\ncommunity grants awarded in 2026. These investments support 230\ncommunity-based organizations in 110 cities across 36 states and territories,\nincluding Puerto Rico, working to ensure that people and communities most\ndisproportionately impacted by HIV have access to the support they need.\n\nThe grants, which were awarded as part of ViiV’s Positive Action program,\nare supporting community-driven solutions to address urgent needs and ensure\nsustained delivery of essential HIV prevention and care services on the\nfrontlines of the HIV response. The funding helps local organizations connect\npeople to care, reduce stigma, expand access, and build stronger systems that\ncan reach people who might otherwise be left behind. By investing in trusted\ncommunity partners, ViiV is helping turn progress in HIV science into\nreal-life impact for the people and places that need it most.\n\n“Scientific progress has transformed what is possible in HIV, but medicines\nalone will not end the epidemic,” said Jean-Bernard Simeon, Senior Vice\nPresident and Head of ViiV Healthcare, U.S. “At a critical moment for the\nU.S. HIV response, community organizations are navigating many real pressures\nwhile continuing to provide essential services. ViiV Healthcare’s investment\nreflects our long-standing commitment to helping communities respond to what\nthey are seeing on the ground with local solutions. We are incredibly proud of\nour grantees who are working tirelessly to help close gaps in HIV prevention\nand care and to keep driving progress where it matters most.”\n\nBuilding on more than three decades globally of sustained Positive Action\nfunding and partnership with community organizations, ViiV Healthcare works\nhand-in-hand with national, regional, and community organizations, advocates,\nand healthcare partners to listen and learn from the people most impacted by\nHIV. These close ties help the company better understand and respond to\nevolving community needs through funding to address disparities and stigma,\nelevate community voices, strengthen connections to prevention and care, and\nsupport locally-driven solutions.\n\nAmong the many organizations supported through this year’s commitment is the\nNational Minority AIDS Council (NMAC), whose NextGen Emerging Leaders\nFellowship\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nmac.org%2Fprograms%2Ftreatment%2Fyouth%2F&esheet=54601919&newsitemid=20260910311785&lan=en-US&anchor=NextGen+Emerging+Leaders+Fellowship&index=1&md5=aef4812422269e6da2363e510177c8a8)\nis helping build a pipeline of young adults prepared to enter and strengthen\nthe HIV workforce through hands-on public health training, professional\ndevelopment, mentorship, and community-based experience. This year’s funding\nbuilds on five years of sustained support that has allowed young adults ages\n18–25 to develop fellow-led projects, including community health events and\npublic health campaigns, focused on HIV testing, prevention, treatment and\nstigma. This week at USCHA, the largest convening of the HIV movement in the\nU.S., the NextGen fellows will showcase the community health projects they\ndeveloped through the program and take part in advanced leadership training\ndesigned to strengthen their ability to drive HIV prevention, education, and\nengagement in their communities.\n\n“Building a stronger HIV response means making sure the next generation has\nthe skills, experience, and opportunity to lead,” said Harold J. Phillips,\nChief Executive Officer, NMAC. “ViiV Healthcare’s support of the NextGen\nEmerging Leaders Fellowship is helping young people turn their lived\nexperience and commitment to community into practical public health\nleadership. That investment is strengthening the HIV workforce today, while\nhelping prepare the leaders our movement will depend on tomorrow.”\n\nTo learn more about ViiV Healthcare’s work to expand access to HIV services\nfor communities disproportionately affected by HIV, visit\nwww.viivhealthcare.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fviivhealthcare.com%2Fen-us%2F&esheet=54601919&newsitemid=20260910311785&lan=en-US&anchor=www.viivhealthcare.com&index=2&md5=f463d5eebc2a68130c5b220592aefa00)\n.\n\nAbout ViiV Healthcare\n\nViiV Healthcare is a global specialist HIV company established in November\n2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is\ndedicated to delivering advances in treatment and care for people living with\nHIV and for people who could benefit from HIV prevention. ViiV Healthcare aims\nto take a deeper and broader interest in HIV and AIDS than any company has\ndone before and take a new approach to deliver effective and innovative\nmedicines for HIV treatment and prevention, as well as support communities\naffected by HIV.\n\nFor more information on the company, its management, portfolio, pipeline, and\ncommitment, please visit viivhealthcare.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fviivhealthcare.com%2Fen-us%2F&esheet=54601919&newsitemid=20260910311785&lan=en-US&anchor=viivhealthcare.com&index=3&md5=0ddcd898ca70c513b9ec79b55e48c3a9)\n.\n\nAbout GSK\n\nGSK is a global biopharma company with a purpose to unite science, technology,\nand talent to get ahead of disease together. Find out more at gsk.com.\n\nCautionary statement regarding forward-looking statements\n\nGSK cautions investors that any forward-looking statements or projections made\nby GSK, including those made in this announcement, are subject to risks and\nuncertainties that may cause actual results to differ materially from those\nprojected. Such factors include, but are not limited to, those described in\nthe “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025,\nand GSK’s Q2 Results for 2026.\n Registered in England & Wales:                                     \n GSK plc                             ViiV Healthcare Limited        \n No. 3888792                         No. 06876960                   \n                                                                    \n                                                                    \n Registered Office:                                                 \n 79 New Oxford Street                ViiV Healthcare Limited        \n London                              GSK Medicines Research Centre  \n WC1A 1DG                            Gunnels Wood Road, Stevenage   \n                                     United Kingdom                 \n                                     SG1 2NY                        \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260910311785/en/\n(https://www.businesswire.com/news/home/20260910311785/en/)\n\nViiV Healthcare enquiries: \n\nMedia:\n\nRachel Jaikaran +1 919 357 8932 (North Carolina)\n\nBithiah Lafontant +1 984 239 4915 (North Carolina)\n\n\n\nGSK enquiries: \n\nMedia:\n\nTim Foley +44 (0) 20 8047 5502 (London)\n\nSarah Clements +44 (0) 20 8047 5502 (London)\n\nKathleen Quinn +1 202 603 5003 (Washington DC)\n\nAlison Hunt +1 540 742 3391 (Washington DC)\n\n\n\nInvestor Relations:\n\nConstantin Fest +44 (0) 7831 826525 (London)\n\nJames Dodwell +44 (0) 20 8047 2406 (London)\n\nMick Readey +44 (0) 7990 339653 (London)\n\nSteph Mountifield +44 (0) 7796 707505 (London)\n\nSam Piper +44 (0) 7824 525779 (London)\n\nJeff McLaughlin +1 215 751 7002 (Philadelphia)\n\nFrannie DeFranco +1 215 751 3126 (Philadelphia)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5MxmJRa-20260915","title":"Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to Advance HIV Response in the U.S.","author":"Business Wire","ticker":"GSK","created":"2026-09-15T12:00:02.783Z","tickers":["GSK"],"exchange":"LSE","article_body":"Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to\nAdvance HIV Response in the U.S.\n\n\n * Ahead of the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare\nannounced it has funded 230 community-based organizations this year to\nstrengthen essential HIV services and help connect people to HIV prevention\nand care\n\nViiV Healthcare, the global specialist HIV company majority owned by GSK, with\nShionogi as a shareholder, today announced more than $33 million in U.S.\ncommunity grants awarded in 2026. These investments support 230\ncommunity-based organizations in 110 cities across 36 states and territories,\nincluding Puerto Rico, working to ensure that people and communities most\ndisproportionately impacted by HIV have access to the support they need.\n\nThe grants, which were awarded as part of ViiV’s Positive Action program,\nare supporting community-driven solutions to address urgent needs and ensure\nsustained delivery of essential HIV prevention and care services on the\nfrontlines of the HIV response. The funding helps local organizations connect\npeople to care, reduce stigma, expand access, and build stronger systems that\ncan reach people who might otherwise be left behind. By investing in trusted\ncommunity partners, ViiV is helping turn progress in HIV science into\nreal-life impact for the people and places that need it most.\n\n“Scientific progress has transformed what is possible in HIV, but medicines\nalone will not end the epidemic,” said Jean-Bernard Simeon, Senior Vice\nPresident and Head of ViiV Healthcare, U.S. “At a critical moment for the\nU.S. HIV response, community organizations are navigating many real pressures\nwhile continuing to provide essential services. ViiV Healthcare’s investment\nreflects our long-standing commitment to helping communities respond to what\nthey are seeing on the ground with local solutions. We are incredibly proud of\nour grantees who are working tirelessly to help close gaps in HIV prevention\nand care and to keep driving progress where it matters most.”\n\nBuilding on more than three decades globally of sustained Positive Action\nfunding and partnership with community organizations, ViiV Healthcare works\nhand-in-hand with national, regional, and community organizations, advocates,\nand healthcare partners to listen and learn from the people most impacted by\nHIV. These close ties help the company better understand and respond to\nevolving community needs through funding to address disparities and stigma,\nelevate community voices, strengthen connections to prevention and care, and\nsupport locally-driven solutions.\n\nAmong the many organizations supported through this year’s commitment is the\nNational Minority AIDS Council (NMAC), whose NextGen Emerging Leaders\nFellowship\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nmac.org%2Fprograms%2Ftreatment%2Fyouth%2F&esheet=54601919&newsitemid=20260910311785&lan=en-US&anchor=NextGen+Emerging+Leaders+Fellowship&index=1&md5=aef4812422269e6da2363e510177c8a8)\nis helping build a pipeline of young adults prepared to enter and strengthen\nthe HIV workforce through hands-on public health training, professional\ndevelopment, mentorship, and community-based experience. This year’s funding\nbuilds on five years of sustained support that has allowed young adults ages\n18–25 to develop fellow-led projects, including community health events and\npublic health campaigns, focused on HIV testing, prevention, treatment and\nstigma. This week at USCHA, the largest convening of the HIV movement in the\nU.S., the NextGen fellows will showcase the community health projects they\ndeveloped through the program and take part in advanced leadership training\ndesigned to strengthen their ability to drive HIV prevention, education, and\nengagement in their communities.\n\n“Building a stronger HIV response means making sure the next generation has\nthe skills, experience, and opportunity to lead,” said Harold J. Phillips,\nChief Executive Officer, NMAC. “ViiV Healthcare’s support of the NextGen\nEmerging Leaders Fellowship is helping young people turn their lived\nexperience and commitment to community into practical public health\nleadership. That investment is strengthening the HIV workforce today, while\nhelping prepare the leaders our movement will depend on tomorrow.”\n\nTo learn more about ViiV Healthcare’s work to expand access to HIV services\nfor communities disproportionately affected by HIV, visit\nwww.viivhealthcare.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fviivhealthcare.com%2Fen-us%2F&esheet=54601919&newsitemid=20260910311785&lan=en-US&anchor=www.viivhealthcare.com&index=2&md5=f463d5eebc2a68130c5b220592aefa00)\n.\n\nAbout ViiV Healthcare\n\nViiV Healthcare is a global specialist HIV company established in November\n2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is\ndedicated to delivering advances in treatment and care for people living with\nHIV and for people who could benefit from HIV prevention. ViiV Healthcare aims\nto take a deeper and broader interest in HIV and AIDS than any company has\ndone before and take a new approach to deliver effective and innovative\nmedicines for HIV treatment and prevention, as well as support communities\naffected by HIV.\n\nFor more information on the company, its management, portfolio, pipeline, and\ncommitment, please visit viivhealthcare.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fviivhealthcare.com%2Fen-us%2F&esheet=54601919&newsitemid=20260910311785&lan=en-US&anchor=viivhealthcare.com&index=3&md5=0ddcd898ca70c513b9ec79b55e48c3a9)\n.\n\nAbout GSK\n\nGSK is a global biopharma company with a purpose to unite science, technology,\nand talent to get ahead of disease together. Find out more at gsk.com.\n\nCautionary statement regarding forward-looking statements\n\nGSK cautions investors that any forward-looking statements or projections made\nby GSK, including those made in this announcement, are subject to risks and\nuncertainties that may cause actual results to differ materially from those\nprojected. Such factors include, but are not limited to, those described in\nthe “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025,\nand GSK’s Q2 Results for 2026.\n Registered in England & Wales:                                     \n GSK plc                             ViiV Healthcare Limited        \n No. 3888792                         No. 06876960                   \n                                                                    \n                                                                    \n Registered Office:                                                 \n 79 New Oxford Street                ViiV Healthcare Limited        \n London                              GSK Medicines Research Centre  \n WC1A 1DG                            Gunnels Wood Road, Stevenage   \n                                     United Kingdom                 \n                                     SG1 2NY                        \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260910311785/en/\n(https://www.businesswire.com/news/home/20260910311785/en/)\n\nViiV Healthcare enquiries: \n\nMedia:\n\nRachel Jaikaran +1 919 357 8932 (North Carolina)\n\nBithiah Lafontant +1 984 239 4915 (North Carolina)\n\n\n\nGSK enquiries: \n\nMedia:\n\nTim Foley +44 (0) 20 8047 5502 (London)\n\nSarah Clements +44 (0) 20 8047 5502 (London)\n\nKathleen Quinn +1 202 603 5003 (Washington DC)\n\nAlison Hunt +1 540 742 3391 (Washington DC)\n\n\n\nInvestor Relations:\n\nConstantin Fest +44 (0) 7831 826525 (London)\n\nJames Dodwell +44 (0) 20 8047 2406 (London)\n\nMick Readey +44 (0) 7990 339653 (London)\n\nSteph Mountifield +44 (0) 7796 707505 (London)\n\nSam Piper +44 (0) 7824 525779 (London)\n\nJeff McLaughlin +1 215 751 7002 (Philadelphia)\n\nFrannie DeFranco +1 215 751 3126 (Philadelphia)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-15T12:00:02.929385432Z","server_sent_at_ms":1789473602929},"received_at":"2026-09-15T12:00:02.985Z","source_url":"https://www.businesswire.com/news/home/20260910311785/en/"},"analysis":{"id":"132584","press_release_id":"143751","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"ViiV Healthcare, the HIV specialist majority owned by GSK, awarded more than $33 million in U.S. community grants for 2026, funding 230 community-based organizations across 110 cities in 36 states and territories including Puerto Rico.\n\nThe grants flow through ViiV's long-running Positive Action program and were announced ahead of the 2026 U.S. Conference on HIV/AIDS, where funded groups such as NMAC's NextGen Emerging Leaders Fellowship will showcase community health projects.\n\nFor GSK the commitment is financially immaterial, but it reinforces brand equity and community relationships in the company's highest-value therapeutic franchise heading into a flagship U.S. HIV event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Suppress or file under CSR/brand — $33 million in HIV community grants from GSK's ViiV unit is reputation news, not market news."},"keyFigures":{"customDimensions":{"programName":"Positive Action","citiesCovered":110,"grantTotalUsd":33000000,"organizationsFunded":230,"statesAndTerritories":36}},"quotedText":"Scientific progress has transformed what is possible in HIV, but medicines\nalone will not end the epidemic","namedEntities":{"people":[{"name":"Jean-Bernard Simeon","role":"Senior Vice President and Head of ViiV Healthcare, U.S."},{"name":"Harold J. Phillips","role":"Chief Executive Officer, National Minority AIDS Council (NMAC)"}],"products":["Positive Action program","NextGen Emerging Leaders Fellowship"],"companies":[{"name":"GSK plc","ticker":"GSK","relationship":"filer; majority owner of ViiV Healthcare"},{"name":"ViiV Healthcare","relationship":"majority-owned HIV specialist subsidiary of GSK; grant issuer"},{"name":"Shionogi","relationship":"minority shareholder in ViiV Healthcare"},{"name":"National Minority AIDS Council (NMAC)","relationship":"grantee"}],"dollarAmounts":[{"amount":"$33 million","context":"more than $33 million in U.S. community grants awarded by ViiV Healthcare in 2026"}]},"materialImpact":{"score":1,"reasoning":"Philanthropic grant announcement from ViiV Healthcare, GSK's majority-owned HIV subsidiary; $33 million is financially immaterial to a large-cap biopharma and carries no earnings, regulatory, or pipeline implications."},"tickerRelevance":{"others":[{"ticker":"4507.T","relevance":"minority shareholder in ViiV Healthcare, GSK's majority-owned HIV subsidiary"}],"primary":"GSK"},"globalImportance":8,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"csr_grant_announcement","issuerAuthored":true,"subsidiaryAuthored":true,"financialMateriality":"negligible"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ViiV Healthcare, the HIV specialist majority owned by GSK, awarded more than $33 million in U.S. community grants for 2026, funding 230 community-based organizations across 110 cities in 36 states and territories including Puerto Rico.\n\nThe grants flow through ViiV's long-running Positive Action program and were announced ahead of the 2026 U.S. Conference on HIV/AIDS, where funded groups such as NMAC's NextGen Emerging Leaders Fellowship will showcase community health projects.\n\nFor GSK the commitment is financially immaterial, but it reinforces brand equity and community relationships in the company's highest-value therapeutic franchise heading into a flagship U.S. HIV event.","key_figures":{"customDimensions":{"programName":"Positive Action","citiesCovered":110,"grantTotalUsd":33000000,"organizationsFunded":230,"statesAndTerritories":36}},"named_entities":{"people":[{"name":"Jean-Bernard Simeon","role":"Senior Vice President and Head of ViiV Healthcare, U.S."},{"name":"Harold J. Phillips","role":"Chief Executive Officer, National Minority AIDS Council (NMAC)"}],"products":["Positive Action program","NextGen Emerging Leaders Fellowship"],"companies":[{"name":"GSK plc","ticker":"GSK","relationship":"filer; majority owner of ViiV Healthcare"},{"name":"ViiV Healthcare","relationship":"majority-owned HIV specialist subsidiary of GSK; grant issuer"},{"name":"Shionogi","relationship":"minority shareholder in ViiV Healthcare"},{"name":"National Minority AIDS Council (NMAC)","relationship":"grantee"}],"dollarAmounts":[{"amount":"$33 million","context":"more than $33 million in U.S. community grants awarded by ViiV Healthcare in 2026"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-15T12:03:13.320Z","global_importance":8,"audience_relevance":18,"importance_components":{"tickerTier":"large-cap","eventGravity":"csr_grant_announcement","issuerAuthored":true,"subsidiaryAuthored":true,"financialMateriality":"negligible"}},"durationMs":39815,"modelName":"glm-5.3-flash"}}